UNITY Biotechnology Competitors

Calico is an Alphabet-founded research and development company whose mission is to harness advanced technologies and model systems to increase our understanding of the biology that controls human aging. We will use that knowledge to devise interventions that enable people to lead longer and healthier lives. Calico’s highly innovative technology labs, its commitment to curiosity-driven discovery science and, with academic and industry partners, its vibrant drug-development pipeline together create an inspiring and exciting place to catalyze and enable medical breakthroughs. Calico is currently seeking exceptional candidates who share our passion for understanding the science of aging and developing therapeutics to address age-related diseases. Explore with us! https://www.calicolabs.com/careers

Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Driven by urgency and guided by purpose, we aim to help patients live with more energy, fewer limitations, and more possibility in everyday life. We bring together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care to pursue what’s next for patients. Our telomerase inhibitor is the first and only of its kind approved in the U.S. and EU for certain patients with lower-risk myelodysplastic syndromes (LR-MDS) and we continue to explore the potential of telomerase inhibition beyond LR-MDS, including in myelofibrosis and other cancers. Our culture is shaped by curiosity, collaboration, accountability and the persistence that has defined Geron from the beginning. The determination that helped transform telomerase inhibition from a bold scientific idea into a clinically validated approach continues to guide how we think, work, and pursue what’s next for patients. Learn more about our science, our people and opportunities to join #TeamGeron at www.geron.com Geron’s Community Guidelines: https://www.geron.com/CommunityGuidelines/